KALV Stock Summary and Trading Ideas (Kalvista Pharmaceuticals | NASDAQ:KALV)

KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.

Kalvista Pharmaceuticals trades on the NASDAQ stock market under the symbol KALV.

As of March 3, 2025, KALV stock price declined to $11.01 with 589,485 million shares trading.

KALV has a beta of 0.99, meaning it tends to be less sensitive to market movements. KALV has a correlation of 0.05 to the broad based SPY ETF.

KALV has a market cap of $544.09 million. This is considered a Small Cap stock.

In the last 3 years, KALV traded as high as $17.35 and as low as $4.12.

The top ETF exchange traded funds that KALV belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWO.

KALV has underperformed the market in the last year with a return of -17.8%, while SPY returned +17.8%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in KALV shares. However, KALV has outperformed the market in the last 3 month and 2 week periods, returning +9.1% and +12.8%, while SPY returned -1.3% and -3.4%, respectively. This indicates KALV has been having a stronger performance recently.

KALV support price is $10.88 and resistance is $11.91 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KALV shares will trade within this expected range on the day.